NCT01626248View on ClinicalTrials.gov

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

CompletedOBSERVATIONAL
Enrollment

164

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

April 30, 2013

Conditions
Multiple Sclerosis
Trial Locations (1)

84103

Rocky Mountain MS Clinic, Salt Lake City

Sponsors
All Listed Sponsors
collaborator

Biogen

INDUSTRY

collaborator

Elan Pharmaceuticals

INDUSTRY

lead

John F. Foley, MD

OTHER